HOTH
Hoth Therapeutics Inc

11,554
Mkt Cap
$15.67M
Volume
289,324.00
52W High
$2.12
52W Low
$0.6554
PE Ratio
-0.95
HOTH Fundamentals
Price
$1.01
Prev Close
$1.04
Open
$1.03
50D MA
$1.01
Beta
1.01
Avg. Volume
677,081.05
EPS (Annual)
-$1.28
P/B
1.86
Rev/Employee
$0.00
$2.24
Loading...
Loading...
News
all
press releases
HOTH THERAPEUTICS ACCELERATES HT-001 TRIAL ENROLLMENT WITH NEW CLINICAL SITE AS PATIENT DEMAND INCREASES
HOTH THERAPEUTICS ACCELERATES HT-001 TRIAL ENROLLMENT WITH NEW CLINICAL SITE AS PATIENT DEMAND INCREASES HOTH THERAPEUTICS ACCELERATES HT-001 TRIAL ENROLLMENT WITH NEW CLINICAL SITE AS PATIENT DEMAND...
PR Newswire·5d ago
News Placeholder
More News
News Placeholder
Hoth Therapeutics Receives U.S. Notice of Allowance for Novel Exon-Skipping Therapy Targeting Allergic Diseases
Hoth Therapeutics Receives U.S. Notice of Allowance for Novel Exon-Skipping Therapy Targeting Allergic Diseases Hoth Therapeutics Receives U.S. Notice of Allowance for Novel Exon-Skipping Therapy...
PR Newswire·18d ago
News Placeholder
Hoth Therapeutics' GDNF Treatment Shows Superior Efficacy Over Wegovy, Ozempic In Preclinical Trial
The company announced positive preclinical results from a study evaluating GDNF as a potential treatment for obesity and metabolic-associated steatotic liver disease.
Stocktwits·19d ago
News Placeholder
Hoth Therapeutics Addresses Market Rumor, Hoth Holds No Crypto Currency Assets
Hoth Therapeutics Addresses Market Rumor, Hoth Holds No Crypto Currency Assets Hoth Therapeutics Addresses Market Rumor, Hoth Holds No Crypto Currency Assets PR Newswire NEW YORK, Feb. 5, 2026 NEW...
PR Newswire·25d ago
News Placeholder
Hoth Therapeutics Early Cancer Trial Succeeds With 100% Patient Response, Cuts Disease Severity By Half
Hoth Therapeutics reported interim trial results showing all patients improved by Week 6, with reduced disease severity, fewer side effects, and early lasting benefits in cancer patients on EGFR...
Benzinga·1mo ago
News Placeholder
Hoth Therapeutics Delivers 100% Clinical Response with ~50% Reduction in Disease Severity in Open-Label PK Cohort of EGFR-Treated Cancer Patients
Hoth Therapeutics Delivers 100% Clinical Response with ~50% Reduction in Disease Severity in Open-Label PK Cohort of EGFR-Treated Cancer Patients Hoth Therapeutics Delivers 100% Clinical Response...
PR Newswire·1mo ago
News Placeholder
Hoth Therapeutics Secures Major International Patent Milestone for HT-KIT Cancer Program, Strengthening Global Oncology IP Position
Hoth Therapeutics Secures Major International Patent Milestone for HT-KIT Cancer Program, Strengthening Global Oncology IP Position Hoth Therapeutics Secures Major International Patent Milestone for...
PR Newswire·1mo ago
News Placeholder
Hoth Therapeutics Reaches Key EU Regulatory Inflection Point Advancing HT-001 Oncology Trial Toward Multi-Country Site Activation
Hoth Therapeutics Reaches Key EU Regulatory Inflection Point Advancing HT-001 Oncology Trial Toward Multi-Country Site Activation Hoth Therapeutics Reaches Key EU Regulatory Inflection Point...
PR Newswire·2mo ago
News Placeholder
Hoth Therapeutics Files Two Provisional Patents To Build Oncology Dermatology Platform
(RTTNews) - Hoth Therapeutics (HOTH) has filed two U.S. provisional patent applications that expand its intellectual property portfolio and lay the foundation for a new oncology-focused dermatology...
Nasdaq News: Markets·2mo ago
News Placeholder
Hoth Therapeutics Expands Oncology Pipeline with Dual Patent Filings Establishing Novel Oncology Dermatology IP Platform
Hoth Therapeutics Expands Oncology Pipeline with Dual Patent Filings Establishing Novel Oncology Dermatology IP Platform Hoth Therapeutics Expands Oncology Pipeline with Dual Patent Filings...
PR Newswire·2mo ago
<
1
2
...
>

Latest HOTH News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.